Teva in Haarlem is an all-round pharmaceutical company, active in all segments of the pharma market. We are a subsidiary of Teva Pharmaceutical Industries, the world’s largest manufacturer of generics medicines and with a growing portfolio of specialty medicines. In our site in Haarlem, the Netherlands, we have R&D, Manufacturing and Sales & Marketing activities. Our R&D focuses on developing complex injectable medicines and medicines for respiratory diseases for the benefit of patients, worldwide. In our factory we manufacture medicines for the treatment of cancer and respiratory diseases that are sold in more than 100 countries worldwide. As a healthcare partner in the Netherlands, we are the largest supplier of medicines for the Netherlands: one out of every five medicine packages that are supplied by pharmacists to patients is a Teva product.
Contact
For more information, please visit us at www.teva.nl
Address: Teva Nederland, Swensweg 5, 2031 GA Haarlem, The Netherlands
Tel: +31 (0)23 5147147
Web: www.teva.nl
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
See our Cookie Privacy Policy Here
